Scholarlink

Background <p>Leukemia is a highly heterogeneous and aggressive hematological malignancy. Current therapeutic approaches (e.g. chemotherapy, radiotherapy, small-molecule targeted therapies, and hematopoietic stem cell transplantation, etc.) are widely limited in clinical practice by systemic drug toxicity, acquired drug resistance, off-target effects, and graft rejection, highlighting the urgent need for safer and more effective innovative treatment strategies.</p> Main body <p>Ligand-targeted nanodelivery systems achieve precise recognition and targeted delivery to tumor cells by modifying the surface of nanocarriers with ligands (e.g. antibodies, aptamers, proteins, peptides, and small molecules, etc.). This review systematically summarizes common therapeutic targets in leukemia, existing treatment agents, and strategies for constructing ligand-functionalized nanocarriers, with a particular focus on the fundamental research and clinical progress of single-ligand and dual-ligand targeted delivery systems. Overall, most studies indicate that dual-ligand systems exhibit superior targeting efficiency and therapeutic performance compared with single-ligand systems; however, clinical translation still faces challenges, including large-scale manufacturing, immunogenicity and systemic toxicity evaluation, regulatory and intellectual property barriers, and the development of humanized models.</p> Conclusions <p>Ligand-targeted nanodelivery systems have been applied in multiple areas of leukemia treatment, including drug delivery, gene therapy, and diagnostic detection. Future research should prioritize the development of combination therapeutic strategies, as well as the diversified application of nanomaterials in ligand modification and immunotherapy models; meanwhile, the integration of artificial intelligence to assist ligand design and optimization may provide new directions for further improving targeted therapeutic strategies for leukemia.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月2日

查看全文
  • Mingxin Hu,
  • Chaoxing He,
  • Jintao Hao,
  • Nannan Qi,
  • Ke He,
  • Bai Xiang,
  • Zhiyun Niu

摘要

Background

Leukemia is a highly heterogeneous and aggressive hematological malignancy. Current therapeutic approaches (e.g. chemotherapy, radiotherapy, small-molecule targeted therapies, and hematopoietic stem cell transplantation, etc.) are widely limited in clinical practice by systemic drug toxicity, acquired drug resistance, off-target effects, and graft rejection, highlighting the urgent need for safer and more effective innovative treatment strategies.

Main body

Ligand-targeted nanodelivery systems achieve precise recognition and targeted delivery to tumor cells by modifying the surface of nanocarriers with ligands (e.g. antibodies, aptamers, proteins, peptides, and small molecules, etc.). This review systematically summarizes common therapeutic targets in leukemia, existing treatment agents, and strategies for constructing ligand-functionalized nanocarriers, with a particular focus on the fundamental research and clinical progress of single-ligand and dual-ligand targeted delivery systems. Overall, most studies indicate that dual-ligand systems exhibit superior targeting efficiency and therapeutic performance compared with single-ligand systems; however, clinical translation still faces challenges, including large-scale manufacturing, immunogenicity and systemic toxicity evaluation, regulatory and intellectual property barriers, and the development of humanized models.

Conclusions

Ligand-targeted nanodelivery systems have been applied in multiple areas of leukemia treatment, including drug delivery, gene therapy, and diagnostic detection. Future research should prioritize the development of combination therapeutic strategies, as well as the diversified application of nanomaterials in ligand modification and immunotherapy models; meanwhile, the integration of artificial intelligence to assist ligand design and optimization may provide new directions for further improving targeted therapeutic strategies for leukemia.